Ignite Creation Date:
2024-05-06 @ 1:08 AM
Last Modification Date:
2024-10-26 @ 10:59 AM
Study NCT ID:
NCT01732757
Status:
COMPLETED
Last Update Posted:
2014-01-14
First Post:
2012-11-19
Brief Title:
A Study to Evaluate the Efficacy of Lastacaft Compared to Pataday and Placebo in Patients With Acute Allergic Conjunctivitis
Sponsor:
Allergan
Organization:
Allergan
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the efficacy of Lastacaft Alcaftadine 025 and Pataday Olopatadine 02 as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None